A cryosurgery machine used in hospitals across all 50 states can build up enough internal pressure to rupture the probe a doctor is holding inside a patient, and the trigger is something as ordinary as a firm tug on a hose.
Erbe USA is correcting 11,226 ERBECRYO 2 cryosurgical units after determining that a strong pull on the high-pressure transfer hose can create what the company calls a pneumatic short circuit between the gas inlet and the connector. Carbon dioxide leaks into the return path, pressure climbs beyond design limits, and the attached cryoprobe can rupture.
The FDA record, posted this month, attributes the cause to device design and classifies the action as Class 2. Unlike most recalls, nothing is being taken away. The machines stay in service while Erbe representatives install updated software.
The Fix Is Software for a Problem That Is Physical
The correction Erbe is deploying updates the unit from software version 1.0.3 to version 1.0.4. An Erbe representative performs the installation on site, and facilities are asked to make the unit available and confirm acknowledgment.
Affected units are model 10402-000 with serial numbers up to 11608268. The company told customers that, while awaiting the update, there is no change to the unit's intended use or performance and that staff should continue to follow all existing warnings and instructions.
That combination is worth reading carefully. The failure mode is mechanical: gas takes an unintended path and pressure rises. The remedy is software, and the recall documentation does not describe how the update addresses the pressure condition.
For hospitals, the practical implication is scheduling. A software correction requires a technician visit per unit, and 11,226 units spread across every state, the District of Columbia, and Puerto Rico is a substantial field service load. Departments that use these units daily will need to coordinate downtime.
Erbe asked facilities to share the notice with all users in the building, recognizing that the people most likely to encounter the hazard are those handling the equipment rather than those managing the purchase records.
Cryosurgery Happens in Places Where a Rupture Is Not Trivial
The ERBECRYO 2 delivers extreme cold through a probe to destroy or grip tissue. It is used heavily in interventional pulmonology, where physicians pass a probe through a bronchoscope into a patient's airway.
Typical applications include removing foreign bodies, clearing mucus plugs, extracting blood clots, taking tissue biopsies, and treating tumors that are obstructing an airway. These are procedures on sedated patients with an instrument inside the lung.
A probe rupture in that setting is not an equipment inconvenience. The FDA's description of an earlier Erbe probe rupture issue notes that the burst produces a loud sound that could cause tinnitus, temporary hearing loss, or persistent hearing loss to patients, health care professionals, or anyone near the device when activated, and that the rupture may also lead to injuries and burns.
The FDA record for this correction does not list any reported injuries. That is a genuine and important limitation on how alarmed anyone should be, and it is also the reason the action carries a Class 2 rating rather than the more serious Class 1 designation.
A Second Route to the Same Failure in One Year
This is not the first federal action this year involving Erbe cryoprobes bursting during use, and the distinction between the two is the part clinicians should understand.
Erbe USA notified customers in February that certain flexible cryoprobes should be removed from use after reports that some ruptured during activation. The FDA later identified that recall as Class 1, its most serious classification, and attributed the failure to insufficient adhesive applied during production, which allowed excessive input pressure. As of late February, Erbe had reported five serious injuries and no deaths connected to that issue. The agency updated the communication in the spring to add further affected lots.
The current action has a different root cause. Rather than a manufacturing defect in the disposable probe, it identifies a design condition in the generator that can send pressure where it does not belong.
Two separate causes producing the same visible failure in a single year is a pattern worth naming plainly, without overstating it. These are distinct FDA records with distinct root causes, and neither document asserts a connection between them. What they share is an outcome: a probe that can burst during a procedure.
Erbe has posted its own recall communications on its US website, and hospitals can confirm affected serial numbers through Erbe's field action notices or by contacting the company directly.
Patients Facing a Bronchoscopy Have Reasonable Questions
Nobody should cancel a needed bronchoscopy or cryobiopsy over this. These procedures diagnose lung cancer, clear dangerous airway obstructions, and resolve conditions that carry far more risk than the device issue does.
Patients scheduled for a cryotherapy procedure can ask whether the facility's ERBECRYO 2 units have received the version 1.0.4 update. That is a fair question, and a hospital's biomedical engineering department will know the answer even if the proceduralist does not.
Anyone who underwent a cryotherapy procedure and experienced ringing in the ears, muffled hearing, or hearing loss afterward should mention it to their physician and consider an audiology evaluation. Hearing changes following a loud acoustic event can be temporary, but persistent symptoms deserve assessment.
Operating room and endoscopy staff have a stake here that patient-focused coverage often skips. The FDA notice on the earlier probe issue is explicit that clinicians standing near an activated device are among those at risk, not only the patient on the table.
Clinicians and patients can report device problems through the FDA's MedWatch reporting program. Those reports are how the agency detects when a defect is more widespread than initial complaints suggest, and both of this year's Erbe actions trace back to reports of that kind.
The recall remains open, which means not all units have been corrected. Hospitals should expect continued outreach from Erbe representatives, and the FDA device recall database will be updated as the status changes. Whether the software update fully resolves the pressure condition, or whether a hardware change follows, is not addressed in the current documentation.
Key Questions Answered
What is the problem with these units? A strong pull on the high-pressure transfer hose can create a pneumatic short circuit between the gas inlet and the connector, letting carbon dioxide leak into the return path. The resulting excessive pressure can rupture the cryoprobe.
How many units are affected? 11,226 ERBECRYO 2 cryosurgical units, model 10402-000, with serial numbers up to 11608268 running software version 1.0.3. Distribution covers all 50 states, the District of Columbia, and Puerto Rico.
Are the machines being removed from hospitals? No. This is a correction rather than a removal. Erbe representatives are installing a software update to version 1.0.4 on site, and the company says there is no change to intended use while facilities await the update.
What are these machines used for? Cryosurgery, particularly in interventional pulmonology. Physicians use them to remove foreign bodies, clear mucus plugs and blood clots, take tissue biopsies, and treat obstructing airway tumors.
Have injuries been reported? The FDA record for this correction does not list reported injuries. A separate Class 1 recall of Erbe flexible cryoprobes earlier this year, caused by insufficient adhesive, reported five serious injuries and no deaths.
Is this the same as the earlier cryoprobe recall? No. The February action removed disposable probes due to a manufacturing defect and was classified as Class 1. This one is a Class 2 correction addressing a design condition in the generator unit. The records do not assert a connection.
Should a patient postpone a scheduled procedure? No. Bronchoscopy and cryobiopsy address conditions that carry far greater risk than this device issue. Patients can ask whether their facility's units have received the version 1.0.4 update.
